Network meta- analysis revealed that in adolescents , intervention with 2000 mg/day metformin ranked better than other interventions ; however , 1000 mg/day metformin for 3 months may be most suitable for adolescents .
For adults , metformin at doses of 3000 and 1000 mg/day ranked the highest , other than minimeal and lifestyle interventions ; moreover , intervention with 3000 mg/day for 6 months and 1000 mg/day for 0.5 months may be suitable for adults .
Conclusion When considering the efficacy of interventions for losing weight , metformin offers clear advantages for overweight and obese population
Purpose Our aim was to assess the efficacy of metformin for weight loss in overweight and obese people through a systematic review and network meta- analysis and to identify the most suitable dosage and intervention period for using metformin  in adolescents and adults .
The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial
Abstract Objective : To compare serum concentrations of inflammatory cytokines , interleukin 6 ( IL-6 ) , high-sensitivity C-reactive protein ( hs-CRP ) , adiponectin , and tumor necrosis factor α ( TNFα ) , before and after 3 months treatment with metformin in obese adolescents with insulin resistance ( IR ) . Design and subjects : This was a r and omized , double-blinded , clinical trial of two groups of obese adolescents with IR , aged 9–18 years : a placebo group ( n=14 ) and a metformin group ( n=12 ) who received 500 mg metformin every 12 h for 3 months  . Anthropometric and biochemical ( metabolic and inflammatory cytokines ) assessment s were compared at the beginning and end of treatment . Results : After 3 months of treatment , body mass index ( kg/m2 ) was reduced in both groups : placebo group ( 32.82±6.37–32.10±6.52 ; p=0.011 ) and metformin group ( 33.44±5.82–32.71±5.77 ; p=0.015 ) . Serum fasting insulin concentrations ( pmol/L ) increased in the placebo group ( 189.45±112.64–266.06±167.79 ; p=0.01 ) and showed a slight decrease in the metformin group ( 256.82±113.89–229.25±86.53 ; p=0.64 ) . Adiponectin concentrations ( μg/mL ) decreased in the placebo group ( 13.17±7.31–5.65±6.69 ; p=0.02 ) , while these remained stable in the metformin group ( 8.57±3.98–7.86±6.23 ; p=0.64 ) . In the metformin group , significant reductions were found in the variances of serum TNFα concentrations ( p=0.006 ; Levene test ) . Conclusion : These results suggest that treating obese adolescents with IR  using metformin for 3 months is an option for patients without response to traditional lifestyle change because metformin improves inflammatory activity , which is an etiological factor in cardiovascular disease development
Network meta- analysis revealed that in adolescents , intervention with 2000 mg/day metformin ranked better than other interventions ; however , 1000 mg/day metformin for 3 months may be most suitable for adolescents .
For adults , metformin at doses of 3000 and 1000 mg/day ranked the highest , other than minimeal and lifestyle interventions ; moreover , intervention with 3000 mg/day for 6 months and 1000 mg/day for 0.5 months may be suitable for adults .
Conclusion When considering the efficacy of interventions for losing weight , metformin offers clear advantages for overweight and obese population
Purpose Our aim was to assess the efficacy of metformin for weight loss in overweight and obese people through a systematic review and network meta- analysis and to identify the most suitable dosage and intervention period for using metformin  in adolescents and adults .